Amlodipine besylate - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for amlodipine besylate and what is the scope of freedom to operate?
Amlodipine besylate
is the generic ingredient in nineteen branded drugs marketed by Cmp Dev Llc, Synthon Pharms, Accord Hlthcare, Alkem, Amneal Pharms Ny, Aurobindo Pharma, Chartwell Rx, China Resources, Cipla, Corepharma, Epic Pharma Llc, Gedeon Richter Usa, Genpharm, Hikma, Hikma Pharms, Invagen Pharms, Lupin, Macleods Pharms Ltd, Mylan, Norvium Bioscience, Orbion Pharms, Oxford Pharms, Polygen Pharms, Puracap Pharm, Sciegen Pharms Inc, Sovereign Pharms, Strides Pharma, Sun Pharm Inds Inc, Sun Pharm Inds Ltd, Sun Pharm Industries, Sunshine, Teva, Torrent Pharms, Unichem, Watson Labs, Wockhardt, Zydus Pharms Usa, Viatris, Apotex, Dr Reddys, Zydus Pharms, Pharmacia, Amneal, Aurobindo Pharma Ltd, Dr Reddys Labs Inc, Heritage, Lupin Pharms, Teva Pharms, Watson Labs Inc, Sandoz, Purple Biotech, Endo Operations, Teva Pharms Usa, Torrent, Cosette, Lupin Ltd, Novartis, Accord Hlthcare Inc, Ajanta Pharma Ltd, Alembic, Alkem Labs Ltd, Glenmark Pharms Ltd, Jubilant Generics, Micro Labs, Adhera, Boehringer Ingelheim, Hetero Labs, and Novel Labs Inc, and is included in one hundred and one NDAs. There are ten patents protecting this compound. Additional information is available in the individual branded drug profile pages.There are twenty-seven drug master file entries for amlodipine besylate. Forty-seven suppliers are listed for this compound. There are three tentative approvals for this compound.
Summary for amlodipine besylate
US Patents: | 10 |
Tradenames: | 19 |
Applicants: | 68 |
NDAs: | 101 |
Drug Master File Entries: | 27 |
Finished Product Suppliers / Packagers: | 47 |
Raw Ingredient (Bulk) Api Vendors: | 125 |
Clinical Trials: | 58 |
Patent Applications: | 7,057 |
Drug Prices: | Drug price trends for amlodipine besylate |
Drug Sales Revenues: | Drug sales revenues for amlodipine besylate |
What excipients (inactive ingredients) are in amlodipine besylate? | amlodipine besylate excipients list |
DailyMed Link: | amlodipine besylate at DailyMed |
Recent Clinical Trials for amlodipine besylate
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Overseas Pharmaceuticals, Ltd. | Phase 1 |
Guangzhou Health Start Pharmaceutical Techology Co.,Ltd | Phase 1 |
Northwestern University | Phase 4 |
Generic filers with tentative approvals for AMLODIPINE BESYLATE
Applicant | Application No. | Strength | Dosage Form |
⤷ Sign Up | ⤷ Sign Up | EQ 10MG BASE | TABLET;ORAL |
⤷ Sign Up | ⤷ Sign Up | EQ 5MG BASE | TABLET;ORAL |
⤷ Sign Up | ⤷ Sign Up | EQ 2.5MG BASE | TABLET;ORAL |
The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.
Pharmacology for amlodipine besylate
Drug Class | Dihydropyridine Calcium Channel Blocker Calcium Channel Blocker |
Mechanism of Action | Calcium Channel Antagonists Cytochrome P450 3A Inhibitors |
Anatomical Therapeutic Chemical (ATC) Classes for amlodipine besylate
US Patents and Regulatory Information for amlodipine besylate
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Alembic | AMLODIPINE BESYLATE AND VALSARTAN | amlodipine besylate; valsartan | TABLET;ORAL | 202713-004 | Apr 3, 2015 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Micro Labs | AMLODIPINE AND OLMESARTAN MEDOXOMIL | amlodipine besylate; olmesartan medoxomil | TABLET;ORAL | 207435-004 | Nov 2, 2017 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Glenmark Pharms Ltd | AMLODIPINE AND OLMESARTAN MEDOXOMIL | amlodipine besylate; olmesartan medoxomil | TABLET;ORAL | 207807-001 | Jul 5, 2017 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for amlodipine besylate
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Viatris | NORVASC | amlodipine besylate | TABLET;ORAL | 019787-002 | Jul 31, 1992 | ⤷ Sign Up | ⤷ Sign Up |
Synthon Pharms | AMLODIPINE BESYLATE | amlodipine besylate | TABLET, ORALLY DISINTEGRATING;ORAL | 022026-001 | Sep 27, 2007 | ⤷ Sign Up | ⤷ Sign Up |
Viatris | NORVASC | amlodipine besylate | TABLET;ORAL | 019787-003 | Jul 31, 1992 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.